Progress in Treatment of Post Inflammatory Pulmonary Fibrosis Induced by SARS-CoV-2 Infection

doi:10.12114/j.issn.1007-9572.2023.0895

Chinese General Practice

1.First Clinical Medical College of Lanzhou University，Lanzhou 730000，China；2.Department of Geriatric Respiratory，the First Hospital of Lanzhou University，Lanzhou 730000，China

Received:2023-11-30 Accepted:2024-01-23
Contact: BAO Hairong，Chief physician； E-mail：baohr9301@163.com

新型冠状病毒诱发的炎症后肺纤维化治疗新进展

1.730000 甘肃省兰州市，兰州大学第一临床医学院；2.730000 甘肃省兰州市，兰州大学第一医院老年呼吸科

通讯作者: 包海荣，主任医师；E-mail：baohr9301@163.com
基金资助:
国家重点研发计划精准医学研究专项 - 呼吸系统疾病专病队列研究（2016YFC0901100）；甘肃省重点研发计划（20YF2FA013）

Abstract

Abstract: Severe acute respiratory syndrome coronavirus 2（SARS-CoV-2）infection is a major public health emergency in the world in the past century，which poses a major threat to the global health system. After rehabilitation from SARS-CoV-2 infection，some patients may experience multiple respiratory symptoms for a long time，which is called the acute sequelae of SARS-CoV-2 infection. Post-COVID-19 pulmonary fibrosis（PCPF）as one of them，can affect the respiratory function and quality of life of patients to varying degrees. Regarding the treatment of PCPF is a hot topic in current research，and this article provides a review of treatment methods for PCPF，aiming to improve the prognosis of PCPF patients.

Key words: SARS-CoV-2, Pulmonary fibrosis, Post-COVID-19 pulmonary fibrosis, Treatment, Review

摘要： 新型冠状病毒（SARS-CoV-2）感染属于近百年全球重大突发公共卫生事件，对全球卫生系统造成重大威胁。SARS-CoV-2 感染康复后部分患者可长时间存在多种呼吸道症状，这被称为 SARS-CoV-2 感染急性期后遗症，SARS-CoV-2 感染后肺纤维化（PCPF）作为其中之一可不同程度地影响患者的呼吸功能和生活质量。有关 PCPF 的治疗是目前研究的热点，本文就 PCPF 的治疗方法做一综述，旨在改善 PCPF 患者的预后。

关键词: 新型冠状病毒, 肺纤维化, 新型冠状病毒感染后肺纤维化, 治疗, 综述

CLC Number:

R 563.13

HUANG Lihui,SHU Juan,$authoret .al. Progress in Treatment of Post Inflammatory Pulmonary Fibrosis Induced by SARS-CoV-2 Infection[J]. Chinese General Practice. DOI: 10.12114/j.issn.1007-9572.2023.0895.
黄丽惠,舒娟,陶会会,等. 新型冠状病毒诱发的炎症后肺纤维化治疗新进展[J]. 中国全科医学. DOI: 10.12114/j.issn.1007-9572.2023.0895.

[1]	NI Jiachun, CAI Zengjin, HOU Changcheng, JIANG Qiong, KANG Jian, YANG Xiangdong, FAN Wenbin. Hemorrhoidal Disease Classification Methods: Recent Advances and Value Analysis [J]. Chinese General Practice, 2024, 27(20): 2545-2550.
[2]	LI Mengye, JIANG Yinong. Recent Advances in Soluble Prorenin Receptor in Multisystem Diseases [J]. Chinese General Practice, 2024, 27(18): 2295-2300.
[3]	KANG Yinnan, SHI Jiaqi, WANG Junke, LI Bin, LI Chuyi, MA Jun, YU Xiaohui. Advances in the Application of Antibody Drug Conjugate in Gastric Cancer with Low Expression of Human Epidermal Growth Factor Receptor 2 [J]. Chinese General Practice, 2024, 27(18): 2287-2294.
[4]	LI Jingjing, ZHENG Gaigai, WANG Yu, LIU Yancun, ZHANG Shuangqi, YANG Qiaofang. A Systematic Review of Symptom Assessment Tools for Patients with Heart Failure [J]. Chinese General Practice, 2024, 27(18): 2272-2278.
[5]	PANG Lan, LI Peifan, ZHU Xiaogang, YANG Zaihong, ZHENG Lei. Deep Transcranial Magnetic Stimulation Combined with Escitalopram Oxalate in the Treatment of Depression: a Randomized Controlled Trial [J]. Chinese General Practice, 2024, 27(17): 2098-2103.
[6]	Primary Healthcare and Health Education Committee of the Guangdong Provincial Health Management Association, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine. Expert Recommendations on the Diagnosis, Treatment, and Care of Post-COVID-19 Conditions for Primary Health Services: Guangdong Province [J]. Chinese General Practice, 2024, 27(17): 2045-2063.
[7]	XU Ziwei, CHENG Kangyao, GUI Li. A Scoping Review of Research on the Management of Surge Hospitals during a Major Infectious Disease Outbreak [J]. Chinese General Practice, 2024, 27(16): 2039-2044.
[8]	NI Xuetong, WANG Ruoxi, ZHANG Jing, YANG Xinghua. Research Progress in the Correlation of Non-alcoholic Fatty Liver Disease and Metabolic-associated Fatty Liver Disease with Cardiovascular Diseases in China and Abroad [J]. Chinese General Practice, 2024, 27(16): 2033-2038.
[9]	ZHONG Ailin, LIU Ailing, ZHOU Shangcheng, GAO Sande, GAO Jing, ZOU Guanyang, CHEN Yingyao. Analysis of Knowledge-attitude-practice Behavior and Influencing Factors for Prevention of Disease in TCM in Community Residents in Guangzhou [J]. Chinese General Practice, 2024, 27(15): 1886-1892.
[10]	WANG Fangfang, ZHU Li, XING Jiajia, PANG Rizhao, GOU Xiang, ZHANG Anren. Research Progress on the Changes of Intestinal Barrier and Possible Mechanism after Traumatic Central Nervous System Injury [J]. Chinese General Practice, 2024, 27(14): 1775-1781.
[11]	ZHAO Yanan, HAN Shifan, LI Ying, ZHOU Liyuan, YANG Jie, WU Jiaxin, CHEN Ganggang. Efficacy of Virtual Reality Vestibular Rehabilitation Training in Patients with Sudden Deafness and Vertigo: a Randomized Controlled Trial [J]. Chinese General Practice, 2024, 27(14): 1672-1677.
[12]	CAO Jiacen, ZHANG Hongkun, ZHAO Wen, NAN Yuemin, LI Dongdong. Progress of Heme Oxygenase-1 Mediated Ferroptosis in Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2024, 27(14): 1782-1788.
[13]	DU Shuqin, QIAN Lifeng, XIONG Lie, SHI Hanqiang, SHI Yanbo. Ferroptosis: a New Target for the Treatment of Depressive Disorder [J]. Chinese General Practice, 2024, 27(12): 1417-1423.
[14]	RAN Dongsheng, LU Yanyan, XIN Chunling, MA Yingcai. Research Progress on the Correlation of Dyslipidemia with Colorectal Serrated Lesions and Colorectal Cancer [J]. Chinese General Practice, 2024, 27(12): 1424-1430.
[15]	LIU Chang, WANG Yufei. Research Status and Prospect of Cross-regional Medical Treatment in China Based on Bibliometric Analysis [J]. Chinese General Practice, 2024, 27(12): 1525-1532.